Organization
Ghent University Hospital, Ghent, Belgium
4 abstracts
Abstract
Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.Org: Saint-Luc University Clinics, Brussels, Belgium, Eugène Marquis Center, Rennes, France, Claude Huriez Hospitals, Lille University Hospital, Lille, France, Ghent University Hospital, Ghent, Belgium, CR UK Liverpool Experimental Cancer Medicine Centre and Clatterbridge Cancer Centre, Liverpool, United Kingdom,
Abstract
ANTI-CENTROMERE ANTIBODY ISOTYPE LEVELS AS BIOMARKER FOR DISEASE PROGRESSION IN SUBJECTS AT RISK TO DEVELOP SYSTEMIC SCLEROSISOrg: Leiden University Medical Center (LUMC), Leiden, Netherlands, Zurich University Hospital, Zurich, Switzerland, Oslo University Hospital, Oslo, Norway, Ghent University Hospital, Ghent, Belgium, Bordeaux University Hospital, Bordeaux, France,
Abstract
BASELINE MRI/CRP AS PREDICTORS OF RESPONSE TO ETANERCEPT IN THE MANAGEMENT OF PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS Org: Diamantina Institute, University of Queensland, University of Queensland & Royal Brisbane and Women's Hospital, Brisbane, Australia, Swedish Medical Center and University of Washington, Seattle, United States of America, Ghent University Hospital, Ghent, Belgium, Pfizer Australia, Sydney, Australia,
Abstract
ANALYSIS OF THE INFLUENCE OF PTPN22 GENE POLYMORPHISMS IN SYSTEMIC SCLEROSIS Org: Instituto de Parasitologia y Biomedicina Lopez-Neyra CSIC, Granada, Spain, University of Texas Health Science Center, Houston, United States, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Hospital Valle de Hebron, Barcelona, Hospital Clínico San Cecilio, Granada, Spain,